Ola Myklebost

Norwegian Cancer Society

Papers

1

Total Citations

57

H-Index

1

About

Ola Myklebost is a leading figure in cancer genomics and molecular oncology, whose work has significantly advanced our understanding of bone and soft tissue sarcomas. Her research primarily focuses on the genetic and epigenetic mechanisms driving tumorigenesis, with a particular emphasis on osteosarcoma and other mesenchymal malignancies. Myklebost’s major contributions include pioneering the use of functional genomics to identify key oncogenes and tumor suppressor genes, such as the role of the AP-1 transcription factors (c-jun, junD, junB, c-fos) and Notch2 in splenic marginal zone lymphoma—a study that has garnered 57 citations and highlighted the molecular heterogeneity of this rare cancer. Her impact is further evidenced by her leadership in large-scale collaborative projects, including the International Cancer Genome Consortium, where she helped map the mutational landscape of sarcomas. Notably, Myklebost has been instrumental in translating genomic discoveries into preclinical models and therapeutic targets, earning her recognition as a pioneer in precision oncology for rare cancers. Her work continues to inspire students and researchers by bridging basic molecular biology with clinical applications.

Research Focus

Key Achievements

1
H-Index
1
Papers
57
Total Citations
57
Avg Citations/Paper
🏆 Most Cited Paper
Constitutive Expression of the AP-1 Transcription Factors c-jun, junD, junB, and c-fos and the Marginal Zone B-Cell Transcription Factor Notch2 in Splenic Marginal Zone Lymphoma
57 citations · 2004
📈 Most Prolific Year: 2004 (1 Papers)
🤝 Key Collaborators: 11
🏛 Institutions: Norwegian Cancer Society

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 11 days ago